Targeted Alpha-Therapy Market Report 2025

The targeted alpha-therapy market size has grown rapidly in recent years. It will grow from $0.87 billion in 2024 to $1.03 billion in 2025 at a compound annual growth rate (CAGR) of 17.4%. The growth during the historic period was driven by increasing regulatory approvals, growing emphasis on targeted therapy over conventional chemotherapy, expanded availability of alpha-emitting isotopes, rising government and private funding, and greater patient preference for minimally invasive therapies.

The targeted alpha-therapy market size is expected to see rapid growth in the next few years. It will grow to $1.93 billion in 2029 at a compound annual growth rate (CAGR) of 17.1%. The growth during the forecast period is fueled by rising prevalence of cancer and metastatic diseases, growing adoption of precision medicine, increasing awareness among oncologists and patients, higher research and development investments, and a growing number of clinical trials. The primary trends in the forecast period include advancements in radiopharmaceutical technology, technological developments in alpha-emitter production, integration of imaging and therapy, improvements in targeted drug delivery systems, and innovations in nuclear medicine technologies.

The increasing emphasis on precision medicine is expected to drive growth in the targeted alpha-therapy market. Precision medicine is an approach that tailors prevention, diagnosis, and treatment to an individual’s genetic makeup, lifestyle, and environment, aiming for more effective outcomes. The rise of precision medicine is largely fueled by the growing availability of genetic testing, which allows for more accurate diagnoses and enables targeted treatments that lead to better patient outcomes. Targeted alpha-therapy plays a key role in precision medicine by delivering potent alpha-emitting isotopes directly to cancer cells. This method ensures precise treatment while minimizing damage to healthy tissues. For example, in March 2024, the American Pharmaceutical Review reported that global spending on precision medicine treatments reached nearly $32 billion in 2022, with projections to exceed $124 billion by 2027. As precision medicine continues to grow, it is expected to further drive the expansion of the targeted alpha-therapy market.

Companies in the targeted alpha-therapy market are innovating with solutions such as peptide receptor radionuclide therapy (PRRT) to improve cancer treatment efficacy, minimize off-target effects, and enhance patient outcomes. PRRT is a targeted cancer treatment that delivers radioactive isotopes directly to tumor cells by binding them to peptides that specifically attach to receptors overexpressed on cancer cells. This helps to minimize damage to healthy tissues. For instance, in February 2024, RadioMedix Inc., a biotechnology company based in the US, partnered with Orano Med, a US-based pharmaceutical company, and received the first targeted alpha therapy to earn FDA breakthrough device designation. Their treatment, AlphaMedix (lead-212-Dotamtate), is designed to treat advanced gastroenteropancreatic neuroendocrine tumors by delivering high-energy alpha radiation directly to cancer cells, sparing healthy tissue. The advantage of this therapy lies in the short path length of alpha particles, which cause lethal DNA damage to tumor cells with minimal toxicity. This approach offers a promising new option for patients who have not responded well to or are naïve to existing beta-emitter treatments, aiming to improve both efficacy and safety in treating difficult neuroendocrine tumors.

In June 2024, AstraZeneca Plc, a UK-based pharmaceutical company, acquired Fusion Pharmaceuticals Inc. for an undisclosed amount. This acquisition allows AstraZeneca to advance its targeted alpha-therapy portfolio and transform cancer treatment by developing next-generation radioconjugate therapies. These new therapies aim to replace traditional chemotherapy and radiotherapy with more precise and targeted options. Fusion Pharmaceuticals Inc., a biotechnology company based in Canada, specializes in targeted alpha-therapy.

Major players in the targeted alpha-therapy market are Bayer Aktiengesellschaft, Novartis AG, Lantheus Holdings Inc., Telix Pharmaceuticals Limited, Eckert & Ziegler Strahlen- und Medizintechnik AG, Actinium Pharmaceuticals Inc., RayzeBio Inc., ITM Isotope Technologies Munich SE, ARTBIO Inc., AdvanCell Pty Ltd., IONETIX Corporation, Abdera Therapeutics Inc., Aktis Oncology Inc., Alpha-9 Oncology Inc., Clarity Pharmaceuticals Pty Ltd., Nucleus RadioPharma, Oncoinvent AS, PanTera, Perspective Therapeutics Inc., RadioMedix Inc.

North America was the largest region in the targeted alpha-therapy market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in targeted alpha-therapy report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the targeted alpha-therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

Targeted alpha therapy (TAT) is a form of radiation therapy that delivers highly potent alpha-particle-emitting isotopes directly to cancer cells or diseased tissues. The therapy employs targeting molecules, such as antibodies, peptides, or small molecules, that specifically bind to cancer cell markers, allowing alpha particles to induce lethal double-strand DNA breaks in nearby cells while minimizing damage to surrounding healthy tissue.

The primary isotope types of targeted alpha therapy are actinium-225, radium-223, lead-212, bismuth-213, and others. Actinium-225 is a potent alpha-emitting radioisotope commonly used in targeted therapies due to its favorable half-life and decay properties. This therapy is applied in conditions such as prostate cancer, bone metastases, pancreatic cancer, and others. Key end users include hospitals, cancer research institutes, specialty clinics, and lymphoma treatment centers.

The targeted alpha-therapy market research report is one of a series of new reports that provides targeted alpha-therapy market statistics, including targeted alpha-therapy industry global market size, regional shares, competitors with a targeted alpha-therapy market share, detailed targeted alpha-therapy market segments, market trends and opportunities, and any further data you may need to thrive in the targeted alpha-therapy industry. This targeted alpha-therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The targeted alpha-therapy market consists of sales of neptunium-225 thorium-227 and astatine-211. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.